Baxter’s Split Into Two Companies Bears Similarity To Abbott’s Biopharma Spinout
This article was originally published in The Pink Sheet Daily
The Illinois-based company will spin out its biopharma business by mid-2015, creating two public companies that will cater to vastly different markets. Yet, both companies are expected to boast strong balance sheets and be in position to make acquisitions.
You may also be interested in...
The proprietary pharmaceuticals business – slated to break off from Abbott on Jan. 1, 2013 – will generate sales of around $18 billion, have a cash balance of $7 billion and an annual R&D spend of around 14% of sales, about $2.52 billion in 2013.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.